Renaissance Technologies
DMRA

Renaissance Technologies’s Damora Therapeutics DMRA Stock Holding History

Renaissance Technologies’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,044
Closed -$56K – 3424
2025
Q3 		$56K Buy
15,044
+500
+3% +$1.69K ﹤0.01% 3323
2025
Q2 		$49.6K Sell
14,544
-800
-5% -$2.37K ﹤0.01% 3393
2025
Q1 		$47.6K Buy
15,344
+300
+2% +$1.41K ﹤0.01% 3294
2024
Q4 		$70K Sell
15,044
-6,338
-30% -$41.5K ﹤0.01% 3340
2024
Q3 		$260K Sell
21,382
-1,790
-8% -$23.4K ﹤0.01% 3033
2024
Q2 		$275K Buy
23,172
+13
+0.1% +$205 ﹤0.01% 2942
2024
Q1 		$452K Buy
23,159
+6,880
+42% +$122K ﹤0.01% 2903
2023
Q4 		$293K Buy
16,279
+8,075
+98% +$124K ﹤0.01% 2998
2023
Q3 		$148K Buy
8,204
+1,570
+24% +$61.6K ﹤0.01% 3159
2023
Q2 		$418K Buy
6,634
+390
+6% +$21.2K ﹤0.01% 2972
2023
Q1 		$311K Buy
6,244
+84
+1% +$4.43K ﹤0.01% 3102
2022
Q4 		$177K Sell
6,160
-1,012
-14% -$42K ﹤0.01% 3464
2022
Q3 		$339K Sell
7,172
-2,696
-27% -$137K ﹤0.01% 3153
2022
Q2 		$427K Buy
9,868
+821
+9% +$37.7K ﹤0.01% 3246
2022
Q1 		$498K Sell
9,047
-161
-2% -$9.04K ﹤0.01% 3201
2021
Q4 		$698K Buy
9,208
+5,092
+124% +$400K ﹤0.01% 2912
2021
Q3 		$369K Buy
4,116
+2,528
+159% +$270K ﹤0.01% 3007
2021
Q2 		$201K Buy
+1,588
New +$216K ﹤0.01% 3245

Other funds holding DMRA

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JG
Jain Global New York $25.4B AUM 45.67% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Renaissance Technologies's DMRA Position: Q4 2025 in Review

Renaissance Technologies sold out of Damora Therapeutics (DMRA) in Q4 2025, closing a stake of 15,044 shares — an estimated $56K sold.

Renaissance Technologies first reported a position in DMRA in Q2 2021 and held it in 18 quarters. The position peaked at $698K in Q4 2021. 18 funds tracked by Wall St. Rank hold DMRA as of Q4 2025.

  • Renaissance Technologies reported no remaining Damora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 15,044 Damora Therapeutics shares in Q4 2025, an estimated $56K.
  • Renaissance Technologies first reported a position in Damora Therapeutics in Q2 2021 and held it in 18 quarters.
  • Renaissance Technologies's Damora Therapeutics position peaked at $698K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.